The biotech sector began 2026 with stellar performance. Over 20 companies reported January revenue growth exceeding 20%, with MBI, PharmaEngine, and Chlitina seeing 100%+ increases. Vizionfocus, Synmosa Biopharma, Applied BioCode (ABC-KY), and Vetnostrum Animal Health all set new monthly records.

• Contact Lenses: Vizionfocus hit a record NT$368 million (+43.41% YoY), while Visco grew nearly 50%, driven by high-end silicone hydrogel products.
• In Vitro Diagnostics (IVD): Applied BioCode reached a record NT$79 million (+88% YoY) due to rising global demand for respiratory and flu testing. Their FDA-cleared multiplex syndromic panels remain highly competitive in North America.
• Flagship Therapeutics: PharmaEssentia reported NT$1.58 billion (+49.82% YoY), the second-highest in its history, on strong global sales of Ropeg.

Resource: 需求火熱 生技股元月營收開門紅